You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in Japan

Apr 2012

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

High pollen levels push up sales of anti-pollen positioned products

Although the exact number of pollen allergic people is unknown, the Ministry of Health, Labour and Welfare quotes a research study that approximately one third of Japan population is afflicted with pollen allergy, with recognised symptoms including a runny nose and watery eyes. The population with pollen allergy is concentrated in urban areas, and the number has been rising. Antihistamines/allergy remedies (systemic) experienced a spike in sales volume in 2011, with the news media estimating pollen levels in 2011 to be five to 10 times the 2010 level. Other anti-pollen positioned products, such as nasal sprays and allergy eye care, experienced significantly larger than average increases in sales volumes.

March earthquake has limited impact on consumer health industry

Although manufacturers and retailers expected demand for OTC products to rise after the March 2011 earthquake, it actually remained constant. One of the major reasons was the relatively small population size of directly affected area. The centre of the shock, Fukushima prefecture, only accounts for 2% of Japan’s entire population. Although news of radiation and aftershocks made consumers in other areas of Japan wary of the severe situation, it was not OTC products which came first to consumers’ minds during the chaos. Instead, news of radiation contaminated water sharply increased demand for bottled water, while energy shortages pushed up sales of energy efficient consumer appliances. Unlike in other fast moving consumer goods, consumers did not drastically reduce the purchase of medication either, as they still considered them as a necessity in their daily lives.

OTC switch creates a major hit product – Loxonin S

Loxoprofen sodium was approved as an OTC active ingredient in early 2010, and Daiichi Sankyo Healthcare Co Ltd launched Loxonin S in January 2011. Within two months of product release, Daiichi Sankyo Healthcare Co Ltd reached its sales objective and Loxonin S became a major hit product in 2011. Prior to the OTC switch, Loxonin was popular as a prescription medicine, with a large number of loyal consumers. After the OTC switch of loxoprofen sodium, the effectiveness of Loxonin S spread by word of mouth, and many female consumers, especially those who suffer from menstrual pain, purchased Loxonin S. The success of Loxonin S indicates the significant market potential of OTC switches products.

Collagen becomes a beauty catalyst among female consumers

More and more women are consuming collagen internally, in addition to its external application in skin care products such as collagen cream and lotions. Many manufacturers are promoting the intake of collagen in various formats, including RTD, tablets and capsules. Collagen is promoted as “beauty essence”, and its image has been further fortified by beauty magazines and TV commercials with celebrity appearances. Although scientific evidence remains vague on the relationship between collagen and skin condition, collagen sales have grown rapidly among beauty-conscious consumers.

Competition poses a threat to sales of tonics and bottled nutritive drinks

Sales of tonics and bottled nutritive drinks are expected to suffer in wider price competition over the forecast period. Since the Drug Deregulation Act introduced in 1999, tonics and bottled nutritive drinks have become widely available in various channels, including supermarkets and convenience stores. With slow economic recovery in Japan, consumers are becoming more price sensitive. As tonics are increasingly placed with other RTD soft drinks on retail shelves, competition and rising price consciousness are putting further pressure on much higher unit price of tonics and bottled nutritive drinks. If manufactures refused to allow discount of retail prices, sales volume is expected to decline due to increased competition and sluggish economic recovery in Japan.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in Japan with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in Japan, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in Japan for free:

The Consumer Health in Japan market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in Japan?
  • What are the major brands in Japan?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in Japan - Industry Overview

EXECUTIVE SUMMARY

High pollen levels push up sales of anti-pollen positioned products

March earthquake has limited impact on consumer health industry

OTC switch creates a major hit product – Loxonin S

Collagen becomes a beauty catalyst among female consumers

Competition poses a threat to sales of tonics and bottled nutritive drinks

KEY TRENDS AND DEVELOPMENTS

High pollen levels in 2011

Rising national debt and potential for OTC switches

Delivery service by parapharmacies/drugstores

Electronic tracking of customer medication usage

Increasing non-store retailing channel sales

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Penetration of Private Label by Category 2006-2011
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

Consumer healthcare registration

Consumer healthcare advertising

Consumer healthcare packaging

Consumer Healthcare Distribution

Regulation of Japanese traditional herbal remedies (kampo)

Vitamins and dietary supplements registration and classification

Self-medication/self-care and preventative medicine

Switches

  • Summary 1 OTC Switches 2009-2011

DEFINITIONS

SOURCES

  • Summary 2 Research Sources

Consumer Health in Japan - Company Profiles

Daiichi Sankyo Healthcare Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 5 Daiichi Sankyo Healthcare Co Ltd: Competitive Position 2011

Fancl Corp in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Fancl Corp: Competitive Position 2011

Hisamitsu Pharmaceutical Co Inc in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 11 Hisamitsu Pharmaceutical Co Inc: Competitive Position 2011

Kobayashi Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 14 Kobayashi Pharmaceutical Co Ltd: Competitive Position 2011

Nichiban Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 17 Nichiban Co Ltd: Competitive Position 2011

Otsuka Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 20 Otsuka Pharmaceutical Co Ltd: Competitive Position 2011

Rohto Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 23 Rohto Pharmaceutical Co Ltd: Competitive Position 2011

Sato Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 26 Sato Pharmaceutical Co Ltd: Competitive Position 2011

Taisho Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 29 Taisho Pharmaceutical Co Ltd: Competitive Position 2011

Takeda Pharmaceutical Co Ltd in Consumer Health (Japan)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 32 Takeda Pharmaceutical Co Ltd: Competitive Position 2011

Adult Mouth Care in Japan - Category Analysis

HEADLINES

TRENDS

  • Value sales of adult mouth care increased slightly in 2011, by 1%. Medication for gum disease, in particular, grew, with rising consumer awareness. Gum disease is said to be one of the major causes of tooth loss. Untreated gingivitis can advance to periodontitis, leading to tooth loss from an abscessed gum. According to the Ministry of Health, Labour and Wellness, 80% of adults in Japan suffer from some form of periodontal disease. Periodontal disease can not only damage gum itself but also has a negative impact through blood circulation, leading to systemic disease. Unlike cavities, gum disease does not cause pain and patients with gum disease often have no subjective symptoms. Middle aged consumers have increased their purchases of adult mouth care to maintain their teeth in later life.

SWITCHES

COMPETITIVE LANDSCAPE

  • Manufacturers adopted different positioning for their promotional campaigns in the latter part of the review period. Instead of focusing on the specifics of the Acess brand, Sato Pharmaceutical Co Ltd emphasised the wide prevalence of gum disease, quoting Ministry of Health, Labour and Wellness statistics. In an Acess TV commercial, an actor warned the audience that four out of five adults are afflicted with gum disease, in order to spread awareness of the possible risk. On the other hand, Lion Corp stressed the effectiveness of Dento Health toothpaste for prevention purposes and maintenance of gum condition.

PROSPECTS

  • Over the forecast period, value sales of adult mouth care are expected to increase by a CAGR of 1% in constant value terms. Since gum disease slowly develops without warning of pain, middle aged consumers are preparing for early treatment. Official statistics on the high percentage of gum disease prevalence are likely to encourage consumers to increase their purchasing of adult mouth care. According to the Ministry of Health, Labour and Welfare, outpatient care has increased since 1999, with visits to doctors most frequently observed among individuals aged between 60 and 69 years old. The Ministry of Health, Labour and Welfare states that the teeth retention rate among elder population has improved, as a result of higher awareness among consumers and consequent early prevention. Since 1989, the Japan Dental Association has been promoting “8020” which means maintaining 20 teeth at the age of 80, and its efforts appear to be paying off. As the number of elderly people increases, the market for adult mouth care is expected to grow steadily.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2006-2011
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 14 Adult Mouth Care Company Shares by Value 2007-2011
  • Table 15 Adult Mouth Care Brand Shares by Value 2008-2011
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in Japan - Category Analysis

HEADLINES

TRENDS

  • Adult analgesics value sales grew by 8% in 2011. Strong growth was observed particularly in combination products – analgesics, where major hit product Loxonin S is included. Loxonin S had sales of over ¥3 billion and quickly gained a market share of 7% in 2011. The launch of Loxonin S helped push up the market size of combination products – analgesics, and the category as a whole grew with other major brands’ favourable sales performances. The top two brands, SSP Co Ltd’s Eve A and Lion Corp’s Bufferin A, increased their sales.

SWITCHES

COMPETITIVE LANDSCAPE

  • With the launch of Daiichi Sankyo Healthcare Co Ltd’s Loxonin S, competition became fiercer in combination products – analgesics in 2011. Brands targeting working women, such as SSP Co Ltd’s Eve A and Lion Corp’s Bufferin A, increased value sales of each brand. Lion renewed the Bufferin series with a campaign featuring the well-known actress Koyuki, while SSP Co Ltd advertised Eve A with actress Ryoko Shinohara. Both companies used actresses popular among women, and the advertising campaigns focused on working women who have work tomorrow and cannot take a day off. Demand for analgesics is high among working women who need to control temporary pain to perform well at work.

PROSPECTS

  • Over the forecast period, value sales of adult analgesics are expected to grow at a CAGR of less than 1%. As the number of working women increases, control of temporary menstrual pain becomes more necessary and the sales are thus expected to grow. Manufacturers will be able to raise sales by promoting positive and strong images of working women and associating these with adult analgesics.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2006-2011
  • Table 19 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011
  • Table 21 Analgesics Company Shares by Value 2007-2011
  • Table 22 Analgesics Brand Shares by Value 2008-2011
  • Table 23 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in Japan - Category Analysis

HEADLINES

TRENDS

  • Value sales of calming and sleeping declined by 4% in 2011, because the market has reached saturation. Sales grew quickly by a CAGR of 31% between 2003 and 2009, with SSP Co Ltd’s launch of Drewell, which was the first OTC medicine to include the active ingredient diphenhydramine hydrochloride. In 2007, other manufacturers entered the market to take advantage of its rapid growth. Taisho Pharmaceutical Co Ltd launched Neody and Resty, while GlaxoSmithKline KK introduced Nytol. However, value sales of calming and sleeping peaked in 2009, and have since declined, with Resty and Nytol exiting the market in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • SSP Co Ltd’s Drewell dominates the calming and sleeping category, with a 61% share in 2011. SSP Co Ltd promoted the concept of “unconscious insomnia” or “kakure fumin”, which refers to a situation where a person with shallow sleep is unaware of his or her insomnia. Most consumers do not identify themselves as needing help from medication to fall asleep unless they see a severe decline in productivity during the day time. SSP Co Ltd tried to deliver the message that the use of calming and sleeping would help to correct individuals’ sleeping pattern, and it is better to rely on medicine temporarily rather than to continue with shallow sleep. SSP Co Ltd created an on-line checklist to help consumers identify “kakure fumin” and established 3 February as “Insomnia Day” to raise consumers’ awareness of the importance of sleep.

PROSPECTS

  • Over the forecast period, value sales of calming and sleeping are expected to decline by an annual average of 2% in constant value terms. Manufacturers have not been able to remove the negative image of using medication to correct sleeping pattern completely from consumers’ mind. With the exit of two major brands and reduced marketing expenditure by the leading company SSP Co Ltd, it will be difficult to bring consumers’ attention back, and the category is thus expected to decline.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2006-2011
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 27 Calming and Sleeping Company Shares by Value 2007-2011
  • Table 28 Calming and Sleeping Brand Shares by Value 2008-2011
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in Japan - Category Analysis

HEADLINES

TRENDS

  • Value sales of antihistamines/allergy remedies (systemic) rose by 22% in 2011 due to very high pollen counts in Japan. It was reported that the dispersion of pollen exceeded 2010 level by 200-1,000%. The highest pollen levels since 2005 caused anxiety among pollen allergic consumers and pushed up sales of antihistamines/allergy remedies (systemic) and decongestants. Decongestants value sales increased by 7% in 2011, and within the category, nasal sprays demonstrated the highest value sales growth of 10%.

SWITCHES

COMPETITIVE LANDSCAPE

  • Taisho Pharmaceutical Co Ltd maintained the leading position in cough, cold and allergy (hay fever) remedies in 2011, with a value share of 16%. Pabron brand sales slightly grew by 2% and contributed to a growth of company sales in 2011. The Pabron brand is present across various categories, including adult and paediatric cough, cold and allergy remedies, decongestants, and pharyngeal preparations. The brand has a long history of over 80 years, and is trusted by consumers as a family brand. Taisho Pharmaceutical Co Ltd has strategically extended the brand across multiple categories to increase sales.

PROSPECTS

  • Value sales of cough, cold and allergy (hay fever) remedies are predicted to decline slightly over the forecast period. Although a high pollen count pushed up sales of the category in 2011, consumers are taking less medication for common cold and cough symptoms. This trend is observed mainly among young consumers, because cough and cold remedies do not address the virus itself but rather reduce the symptoms temporarily. Increasing numbers of consumers are recovering from common coughs and colds without any medication, and the trend is expected to continue. Manufacturers will need to promote early medication to suppress symptoms temporarily to maintain physical strength to fight the virus internally, and communicate how medication can help speed up recovery from common colds and coughs.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 33 Sales of Decongestants by Category: Value 2006-2011
  • Table 34 Sales of Decongestants by Category: % Value Growth 2006-2011
  • Table 35 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 36 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2007-2011
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2008-2011
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in Japan - Category Analysis

HEADLINES

TRENDS

  • Value sales of digestive remedies declined by 2% in 2011. The continued economic downturn and consumers’ reduced dining at restaurants and bars discouraged sales of digestive remedies. Japanese companies often organise “nomikai” or drinking sessions to meet with clients and to strengthen the bonds among colleagues. However, after the March 2011 earthquake, many companies officially restrained from “nomikai” out of respect to the sufferers in the Tohoku region. During spring, it is common for Japanese to gather under cherry blossom trees and drink alcohol, but concerns of radiation leakage discouraged public drinking outside and led to a contraction in the digestive remedies category in Japan.

SWITCHES

COMPETITIVE LANDSCAPE

  • Biofermin, from Biofermin Pharmaceutical Co Ltd, is the leading brand in antiflatulents, which was the only category in digestive remedies which saw positive growth in 2011. It increased its share slightly in 2011. Biofermin Pharmaceutical Co Ltd added three kinds of lactic-acid bacilli which exist in healthy individuals’ bowels. The TV commercials for Biofermin emphasise that it can be taken by pregnant women and babies, stressing the safety of the medication. Biofermin’s gentle formula suited the consumer trend of reduced alcohol consumption and nomikai in 2011.

PROSPECTS

  • Over the forecast period, value sales of digestive remedies are expected to decline by an annual average of 1% in constant value terms. The slow recovery of the economy and the continued trends of less frequent drinking sessions and the rising popularity of non-alcohol beer and cocktails will further hamper sales of digestive remedies. Value sales of digestive remedies are highly influenced by consumers’ eating and drinking habits. However, stomach pain does not result only from excessive drinking, over-eating and food poisoning. Stress from work or human relationships can also cause major discomfort in the stomach. Rather than always associating stomach pain with excessive eating or drinking, manufacturers are starting to introduce remedies to treat stomach pain resulting from stress, and those new type of digestive remedies are anticipated to perform well over the forecast period.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 43 Digestive Remedies Company Shares by Value 2007-2011
  • Table 44 Digestive Remedies Brand Shares by Value 2008-2011
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in Japan - Category Analysis

HEADLINES

TRENDS

  • Tinnitus is the perception of sound within the human ear in the absence of corresponding external sound. There are various studies about tinnitus patients, and the number varies depending on research methods, but it is estimated that roughly 30% of population aged over 65 years old experience ringing in the ears at some point. However, only a fraction of those 30% suffer from chronic disturbance in the ear and the market for ear care saw declining sales with market saturation in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • Kobayashi Pharmaceutical Co Ltd is the dominant player in ear care, with a value share of 97% in 2011. However, the company reported the decline in sales of its Naripitan brand due to reduced marketing expenditure and limited awareness of consumers about ear care products. Kobayashi Pharmaceutical Co Ltd reduced marketing expenditure since it did not generate the expected revenue increase.

PROSPECTS

  • Over the forecast period, sales of ear care are expected to decline by a CAGR of -2%. The dominant player Kobayashi Pharmaceutical Co Ltd’s stagnating sales and still unknown cause of ear ringing from a medical perspective will constrain growth in ear care sales. Currently, there is no identified cause of tinnitus and thus there is no medication in the market to treat all causes of ear ringing. The uncertain nature of symptoms and cure means that the market for OTC ear care is not promising.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2006-2011
  • Table 48 Sales of Ear Care: % Value Growth 2006-2011
  • Table 49 Ear Care Company Shares by Value 2007-2011
  • Table 50 Ear Care Brand Shares by Value 2008-2011
  • Table 51 Forecast Sales of Ear Care: Value 2011-2016
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2011-2016

Eye Care in Japan - Category Analysis

HEADLINES

TRENDS

  • Value sales of eye care rose by 4% in 2011. Allergy eye care grew particularly strongly, by 30%, because of reports that the dispersion of pollen would exceed the 2010 level by 200-1,000%. One of the worst pollen dispersion since 2005 caused anxiety among pollen allergic consumers and pushed up sales of allergy eye care. In Japan, more than 20% of the population is said to suffer from pollen allergy and recognised symptoms include runny nose and water eyes. The pollen allergy population is concentrated in urban areas. The number of sufferers has been rising and demand for anti-pollen medication is high.

SWITCHES

COMPETITIVE LANDSCAPE

  • Rohto Pharmaceutical Co Ltd maintained its top share of 33% in the eye care category in 2011. Its smaller Alguard brand has two separate series – Gold and Silver – depending on the severity of symptoms. Gold is recommended for pollen allergic consumers with severe symptoms, while Silver is positioned for less serious symptoms. Although the unit price of Gold and Silver eye drops is over ¥1,400, sales grew due to strong demand from allergy sufferers. Consumers unsatisfied with other regular eye drops increased their purchasing of Alguard for its perceived effectiveness. Rohto Pharmaceutical Co Ltd also offers products in other categories, such as antihistamines/allergy remedies (systemic) and nasal sprays, and the company promoted Alguard brand as a single solution for multiple pollen allergic symptoms. Its being a trusted brand with strong effectiveness appealed to consumers and encouraged brand loyalty.

PROSPECTS

  • Sales of allergy eye care jumped by 30% due to a large dispersion of pollen in 2011 caused by the one of the hottest summer in the last 30-years. 2010’s prolonged hours of sunlight in eastern parts of Japan exacerbated 2011 pollen dispersion. In the absence of such abnormal weather in 2012, demand for allergy eye care is expected to return to more typical levels with sales falling by 19% in constant value terms in 2012. From 2012 to 2016, allergy eye care is anticipated to see a CAGR of 2%. The majority of Japanese forests are constituted by cedar and cypress trees, which are generating an increasing amount of pollen due to climate change. In addition to rising temperatures, concrete-covered areas exacerbate pollen dispersion, especially in urban areas. Japan’s pollen allergic population is expected to increase and demand for anti-pollen eye care products will thus rise over the forecast period.

CATEGORY DATA

  • Table 53 Sales of Eye Care by Category: Value 2006-2011
  • Table 54 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 55 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 56 Standard Eye Care by Positioning: % Value Breakdown 2007-2011
  • Table 57 Eye Care Company Shares by Value 2007-2011
  • Table 58 Eye Care Brand Shares by Value 2008-2011
  • Table 59 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 60 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in Japan - Category Analysis

HEADLINES

TRENDS

  • In Japan, kampo products are the most well-known type of herbal medicine, and they usually contain several unrefined medications in raw or natural form to treat various symptoms. Widely available through drugstores and supermarkets, kampo has an established status in the OTC market as Category 2 drugs. Unlike herbal products typically classified as supplements in Western countries, kampo products are treated as legitimate medication and consumers view them as reliable solutions for illness.

COMPETITIVE LANDSCAPE

  • Miki Corp continues to lead the market for herbal/traditional products. Although the company’s share has declined slightly compared to that of 2010, due to the ageing of its customer base, Miki Corp still has a strong presence in the market with its top selling product Miki prune extract. Miki Corp is a direct selling company and successfully positioned its Miki prune as premium brand, with a well-known TV commercial. Since 1996, Miki Corp has been using the same actor, Kiichi Nakai, to promote Miki prune extract, and well-balanced nutrition intake is emphasised in the commercial. Miki Corp’s established status in the market is owed in large part to its well-known TV commercial. Additionally, Miki’s prune extract appeals to consumers more than vitamins, which consumers often consider to be artificial products.

PROSPECTS

  • Over the forecast period, a CAGR of rather less than 1% in constant value terms is expected for the market for herbal/traditional products. Since kampo is a traditionally practiced medicine, the market is not expected to move significantly unless there is a specific factor causing demand to rise, such as large dispersion of pollen of the type observed in 2011. Among the various kampo medicines, diuretics and kakkontou will continue to be the main sales drivers.

CATEGORY DATA

  • Table 61 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 62 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 63 Herbal/Traditional Products Company Shares 2007-2011
  • Table 64 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 65 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 66 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in Japan - Category Analysis

HEADLINES

TRENDS

  • Value sales of vaginal antifungals rose by 6% in 2011. Female consumers are switching from prescription to OTC medications due to the sensitive nature of a vaginal yeast infection. Te self-medication trend is growing in vaginal antifungals as consumers prefer purchasing OTC medicines rather than consulting a doctor, in order to keep the symptoms more private. As an increasing number of women are entering the workforce, the level of stress is rising and an associated reduction in the effectiveness of the immune system can cause an imbalance in the bacteria present in the vagina. Use of birth control pills and antibiotics can also cause a similar unbalance, and the number of patients with a vaginal yeast infection is gradually increasing in Japan.

SWITCHES

COMPETITIVE LANDSCAPE

  • The seriousness of hair loss and the willingness to pay a premium for hair loss treatments differs among age groups, and each brand is strategically positioned to appeal to particular consumers. Kao Corp’s Success targets younger men, with the brand slogan of “lasting youth”. With affordable pricing and TV commercials featuring a 27-year old actor, Success is often used as an entry product for hair loss treatments. The Success brand has gained support from younger consumers and raised its value share by almost one percentage point in 2011. Taisho Pharmaceutical Co Ltd’s brand RiUP, which leads category sales, offers two separate ranges to capture different age segments. RiUP X5 is aimed at older men, while RiUP Plus is marketed towards younger consumers. The major difference is the amount of active ingredient minoxidil. RiUP X5 contains five times the amount in RiUP Plus. Strong growth for RiUP X5 contributed to brand share growth, with a rise of four percentage points in share for RiUP overall in 2011.

PROSPECTS

  • Over the forecast period, value sales of medicated skin care are expected to grow by a CAGR of 1% in constant value terms. The major contribution will come from growth in hair loss treatments, with a predicted CAGR of 3%. The population aged over 65 years accounts for 23% of the total, and the number in this age group is expected to increase by a CAGR of 3% over the forecast period. The middle aged population in Japan is highly conscious of appearance and health, with a desire for youthful looks. Manufacturers can benefit if they can develop effective products with distinctive marketing campaigns to encourage category growth.

CATEGORY DATA

  • Table 67 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 68 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 69 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 70 Medicated Skin Care Brand Shares by Value 2008-2011
  • Table 71 Hair Loss Treatments Brand Shares by Value 2008-2011
  • Table 72 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 73 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in Japan - Category Analysis

HEADLINES

TRENDS

  • Value sales of NRT smoking cessation aids increased by 2% in 2011. Although there was a heated discussion about a possible tax increase in 2011, the proposal was not accepted, but it will be revisited in 2012. In 2010, tobacco tax increased by 10% – the highest increase in Japanese history. With multiple taxes, including national, regional, special taxes and VAT, over 50% of cigarette RSP is comprised of tax. With this pricing structure of cigarettes, a 10% tax increase for tobacco translates into an RSP increase of ¥60 to ¥140 per pack.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson KK maintained the leading share of 79% in 2011. Johnson & Johnson KK’s Nicorette brand grew by 2% in that year. Nicorette was the first brand to introduce NRT smoking cessation aids in Japan, in 2001, and the market started with only NRT gum. Consumers regard Nicorette as a leading brand and its relatively long history in Japan make the brand trusted. Johnson & Johnson KK started a campaign on its website asking consumers to make a public statement of quitting smoking using their Facebook or Twitter accounts. Within a month, over 1,200 consumers had participated on-line and made their New Year resolution public. As sales of NRT smoking cessation aids tend to rise after New Year, the campaign encouraged consumer purchasing.

PROSPECTS

  • Over the forecast period, the market for NRT smoking cessation aids is expected to grow by a CAGR of 1%. NRT gum value sales will rise by a CAGR of 2% while NRT patches will decline by an annual average of 2%. As more regional public smoking bans and tax increases on tobacco are forthcoming, demand for NRT smoking cessation aids will continue to rise among smokers. Depending on the progress of regulatory revisions, sales of NRT smoking cessation aids may fluctuate.

CATEGORY INDICATORS

  • Table 74 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 75 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 76 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 77 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 78 NRT Smoking Cessation Aids Company Shares by Value 2007-2011
  • Table 79 NRT Smoking Cessation Aids Brand Shares by Value 2008-2011
  • Table 80 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 81 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

Sports Nutrition in Japan - Category Analysis

HEADLINES

TRENDS

  • Sports nutrition sales grew by 1% in 2011. Rising health consciousness and a boom in running helped push category growth, aided by manufacturers continuously launching new products. Running is a foundation of many sports, and helps build up an individual’s physical strength. According to a study by the Japan Productivity Centre, the number of people who enjoy running and jogging has risen to approximately 28 million people. One of the key running events, the Tokyo Marathon, received 2.7 million applications in 2010 for a limited space of 32,000. Japan’s running boom is being led by heath conscious office workers who run after work near the Imperial Palace in Tokyo. “Bi-jogger” or “beautiful jogger” has become a key term among young women, and major fashion magazines such as FRaU have published featured articles about jogger fashion and sports items.

COMPETITIVE LANDSCAPE

  • Ajinomoto Co Inc leads the sports nutrition category with its amino acid brand Amino Vital. Ajinomoto Co Inc holds a 71% share in non-protein products with its various product offerings under the Amino Vital brand. Amino Vital is offered in various formats, including tablets, RTD, jelly and powder. The company also has a sub-brand, Amino Vital Capsi, an amino acid product with a strong emphasis on the fat burning effect of capsicum. Amino Vital’s strength lies in its availability in various consumption formats and its sub-brand specifically catering for female consumers needs. Amino Vital is available in a wide range of distribution channels, including supermarkets, and its exposure to consumers is unmatched by any other amino acid brands in the market.

PROSPECTS

  • Over the forecast period, a CAGR of 1% in constant value terms is anticipated for sports nutrition. Across all age groups, more and more people are actively exercising in Japan. The Health Insurance Act in Japan introduced “Metabo-kenshin” or mandatory health check-ups for individuals aged between 40 and 74 years, to identify Metabolic Syndrome. The mandatory health check-up enables the early diagnosis of lifestyle diseases, and has encouraged more middle aged workers to exercise regularly. Among young people, exercise is more often tied with beauty and trendiness rather than health. Fashionably dressed runners have been featured in multiple magazines, and celebrity participation in major marathon events has contributed to the boom in running.

CATEGORY DATA

  • Table 82 Sales of Sports Nutrition: Value 2007-2011
  • Table 83 Sales of Sports Nutrition: % Value Growth 2007-2011
  • Table 84 Sports Nutrition Company Shares 2007-2011
  • Table 85 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 86 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in Japan - Category Analysis

HEADLINES

TRENDS

  • Value sales of vitamins and dietary supplements rose by 1% in 2011. With rising health consciousness and an increasing number of middle aged and older consumers, both vitamins and dietary supplements saw positive growth in 2011. A proactive attitude has been observed among middle aged consumers towards anti-ageing and enthusiasm to enjoy life. In order to maintain their health and wellness, dietary supplements with anti-ageing claims, such as glucosamine, have sold well, and consumers’ interest in the early prevention of lifestyle diseases is increasing. In vitamins, products with a beauty positioning rather than just health saw sales grow, and the age group of purchasers widened, with more young female consumers taking vitamins to improve their skin condition.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Taisho Pharmaceutical Co Ltd maintained the top value share of 7% in 2011, although the company saw a marginal share decline compared to 2010. The decline resulted from an unfavourable sales performance of tonics and bottled nutritive drinks, where the company has the leading brand, Lipovitan. Lipovitan accounted for 88% of the company’s vitamins and dietary supplements sales, and the contraction in sales of tonics impacted the company’s performance negatively. The second ranked manufacturer, Otsuka Pharmaceutical Co Ltd, increased its share slightly in 2011. Otsuka Pharmaceutical Co Ltd introduced a new “super” series of multivitamins and fish oil, under its leading brand Nature Made. The new product range emphasises the convenience of one tablet consumption per day, and brand sales grew by 3% in 2011. Additionally, the favourable performance of vitamins and fish oils overall contributed to sales growth for Nature Made.

PROSPECTS

  • Over the forecast period, value sales of vitamins and dietary supplements are expected to rise by a CAGR of rather below 1% in constant value terms. With the rising trend for healthy lifestyles, consumers are increasing their purchases of vitamins and dietary supplements. Middle aged consumers, in particular, have demonstrated a strong interest in vitamins and dietary supplements to improve their health, and anti-ageing positioned products are predicted to see their sales continue to grow over the forecast period. Middle aged and elderly consumers are not used to the concept of OTC self-medications as they grew up with universal health insurance funded by the Japanese government, and the Pharmaceutical Affairs Law revision has not shifted their purchasing patterns significantly. Instead, they are increasingly purchasing vitamins and dietary supplements because they regard such products as a sort of artificial food item without side effects, and they are more comfortable using vitamins and dietary supplements based on their own judgement, without any doctor’s advice. As Japanese society ages, the category is expected to see positive growth in the forecast period.

CATEGORY DATA

  • Summary 33 Dietary Supplements: Brand Ranking by Positioning 2011
  • Table 87 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 88 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 89 Dietary Supplements by Positioning 2006-2011
  • Table 90 Vitamins and Dietary Supplements Company Shares by Value 2007-2011
  • Table 91 Vitamins and Dietary Supplements Brand Shares by Value 2008-2011
  • Table 92 Vitamins Brand Shares by Value 2008-2011
  • Table 93 Dietary Supplements Brand Shares by Value 2008-2011
  • Table 94 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 95 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016

Weight Management in Japan - Category Analysis

HEADLINES

TRENDS

  • Sales of weight management declined by 2% in 2011, largely due to the poor performance of meal replacement slimming. The majority of meal replacement slimming products are targeted at young and middle aged women, but their methods of weight management are diversifying. More and more consumers are actively exercising to lose weight, instead of relying exclusively on meal replacement slimming and weight loss supplements. The exercise industry is increasing its presence in the wider weight control market. According to the Ministry of Trade, Economy and Industry, membership of fitness clubs has increased by 78% compared to what it was in 2000, reaching over 200 million people in 2011. Exercise DVDs, such as Jung Dayeon’s Figurerobics, have become very popular, and her exercise book has sold over 380,000 copies.

COMPETITIVE LANDSCAPE

  • Fancl Corp maintained its leading position in 2011, with a value sales share of 15%. Although the company reported a decline due to the March 11 earthquake in Tohoku, increasing sales of Fancl Calolimit helped sustain its leading position in the weight management category. Calolimit is a weight loss supplement which suppresses the absorption of excess calories. Consumers who repeat the cycle of limiting food intake and then overeating as a result of stress during the diet period often prefer supplements. TV commercials for Calolimit spread product awareness among consumers, and its wide availability in multiple outlets, including convenience stores, helped increase product exposure at the retail level.

PROSPECTS

  • Over the forecast period, sales of weight management products are expected to decline by an annual average of 1% in constant value terms. One of the main reasons for the market contraction is the diversification of weight reduction methods among consumers. However, given the exercise boom, manufacturers of weight managements could introduce new products for consumers who exercise regularly. For example, with exercise it normally takes longer for the body to show any measurable effects, and meal replacement slimming with a sports positioning may well appeal to consumers. These would be more moderate in calorie reduction and with a greater emphasis on tastiness and fullness. A specific nutritional intake in addition to muscle building ingredients such as protein might be suitable for busy working individuals who do not have time to prepare healthy meals after an hour of jogging.

CATEGORY DATA

  • Table 96 Sales of Weight Management: Value 2006-2011
  • Table 97 Sales of Weight Management: % Value Growth 2006-2011
  • Table 98 Weight Management Company Shares 2007-2011
  • Table 99 Weight Management Brand Shares 2008-2011
  • Table 100 Forecast Sales of Weight Management: Value 2011-2016
  • Table 101 Forecast Sales of Weight Management: % Value Growth 2011-2016

Wound Care in Japan - Category Analysis

HEADLINES

TRENDS

  • In 2011, value sales of wound care rose by just under 1%. Value sales of sticking plasters/adhesive bandages grew moderately, by 1%, while gauze, tape and other wound care experienced a decline of 1%, due to in part to the increased presence of private label. Although wound care items are necessities in consumer life and a sudden drop in sales volume is not expected, the growing presence of private label is increasing price competition, especially in gauze, tape and other wound care.

COMPETITIVE LANDSCAPE

  • Johnson & Johnson KK leads the wound care category with 21% of value sales in 2011. It saw a marginal decline in value share in that year, because the company did not launch any new products in the category. However, the Kizu Power Pad series, under the Band-Aid brand, remained popular among consumers, despite its high unit price, with one of the largest sizes costing over ¥100 per single bandage. TV commercials for Kizu Power Pad helped spread awareness of moist healing. Moist wound healing reduces scarring and promotes faster healing by preventing wounds from drying out. Consumers, particularly women, are prepared to pay a premium for its superior ability in reducing scars.

PROSPECTS

  • Over the forecast period, value sales of sticking plasters/adhesive bandages are expected to grow by a CAGR of 1%, while gauze, tape and other wound care will experience a slight annual average decline. Manufacturers have introduced premium adhesive bandages and have convinced consumers that they are worth the extra expense, slowing the trend of price competition. On the other hand, manufacturers have not been able to come up with new innovative products in gauze, tape and other wound care, and the increasing presence of private label is driving prices down. Unless manufacturers can introduce new value-added products which appeal to consumers, it will be difficult to change the direction of the market, particularly given poor consumer confidence in the economy.

CATEGORY DATA

  • Table 102 Sales of Wound Care by Category: Value 2006-2011
  • Table 103 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 104 Wound Care Company Shares by Value 2007-2011
  • Table 105 Wound Care Brand Shares by Value 2008-2011
  • Table 106 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 107 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Agaricus
            • Microalgae
            • Prune Extract
            • Ukon
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
            • Amino Acid
            • Collagen
            • Other Other Non-Herbal Dietary Supplements
      • Tonics and Bottled Nutritive Drinks
      • Vitamins
        • Multivitamins
        • Single Vitamins
          • Vitamin A
          • Vitamin B
          • Vitamin C
          • Vitamin D
          • Vitamin E
          • Other Single Vitamins
    • Weight Management
      • Meal Replacement Slimming
      • OTC Obesity
      • Slimming Teas
      • Weight Loss Supplements
      • Other Slimming Products
    • Herbal/Traditional Products
      • Herbal/Traditional Analgesics
      • Herbal/Traditional Calming and Sleeping Products
      • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
      • Herbal/Traditional Digestive Remedies
      • Herbal/Traditional Medicated Skin Care
      • Herbal/Traditional Medicinal Teas
      • Herbal/Traditional Smoking Cessation Aids
      • Herbal/Traditional Paediatric Dietary Supplements
      • Herbal/Traditional Dietary Supplements
      • Herbal/Traditional Tonics and Bottled Nutritive Drinks
    • Allergy Care
      • Allergy Eye Care
      • Antihistamines/Allergy Remedies (Systemic)
      • Paediatric Allergy Remedies
      • Topical Allergy Remedies/Antihistamines
    • Paediatric Consumer Health
      • Paediatric Analgesics
        • Paediatric Acetaminophen
        • Paediatric Aspirin
        • Paediatric Combination Products - Analgesics
        • Paediatric Diclofenac
        • Paediatric Dipyrone
        • Paediatric Ibuprofen
        • Paediatric Ketoprofen
        • Paediatric Naproxen
      • Paediatric Cough, Cold and Allergy Remedies
        • Paediatric Allergy Remedies
        • Paediatric Cough/Cold Remedies
      • Paediatric Digestive Remedies
        • Paediatric Diarrhoeal Remedies
        • Paediatric Indigestion and Heartburn Remedies
        • Paediatric Laxatives
        • Paediatric Motion Sickness Remedies
      • Paediatric Medicated Skin Care
      • Nappy (Diaper) Rash Treatments
      • Paediatric Vitamins and Dietary Supplements

Statistics Included

Statistics Included

For each category and subcategory you will receive the following data in Excel format:

From Passport

  • Market sizes
  • Company shares
  • Brand shares
  • Distribution
  • Analysis by format
  • Analysis by positioning
  • Analysis by type
  • Herbal/traditional vs standard
  • Pricing
  • Smoking population - number of adult smokers
  • Smoking prevalence - % of adult population

Market size details:

  • Retail volume
  • Retail volume % growth
  • Retail volume per capita
  • Retail value retail selling price % growth
  • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price % growth
  • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
  • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

Methodology

Methodology

Global insight and local knowledge

With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

Industry specialists

Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

Country and regional analysts

Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

In-country research network

To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

Research Methodology

Our research methods

Each Euromonitor International industry report is based on a core set of research techniques:

Desk research

With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

  • National statistics offices governmental and official sources
  • National and international trade press
  • National and international trade associations
  • Industry study groups and other semi-official sources
  • Company financials and annual reports
  • Broker reports
  • Online databases
  • The financial, business and mainstream press

Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

Store checks

Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

  • Place: We track products in all relevant channels, selective and mass, store and non-store
  • Product: What are innovations in products, pack sizes and formats?
  • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
  • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

Trade survey

Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

Trade surveys allow us to:

  • Fill gaps in available published data per company
  • Generate a consensus view of the size, structure and strategic direction of the category
  • Access year-in-progress data where published sources are out of date
  • Evaluate the experts’ views on current trends and market developments

In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

Company analysis

At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

Forecasts

Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

Data validation

All data is subjected to an exhaustive review process, at country, regional and global levels.

The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

Market analysis

Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

my pages

Want to find out more about this report?

If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!